Advisors Asset Management Inc. Has $1.15 Million Stake in United Therapeutics Corporation $UTHR

Advisors Asset Management Inc. raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 4,013 shares of the biotechnology company’s stock after purchasing an additional 121 shares during the quarter. Advisors Asset Management Inc.’s holdings in United Therapeutics were worth $1,153,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its stake in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock valued at $1,374,001,000 after acquiring an additional 15,312 shares during the period. Assetmark Inc. grew its holdings in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of United Therapeutics by 0.7% during the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock valued at $192,571,000 after purchasing an additional 4,145 shares during the period. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of United Therapeutics by 22.5% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock valued at $147,278,000 after purchasing an additional 87,664 shares in the last quarter. Finally, Invesco Ltd. lifted its position in United Therapeutics by 46.1% in the first quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock worth $143,381,000 after purchasing an additional 146,664 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $400.56, for a total transaction of $9,012,600.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 578,435 shares of company stock valued at $252,731,147 over the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Trading Down 0.5%

NASDAQ UTHR opened at $485.97 on Monday. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $492.62. The company has a 50 day moving average of $447.65 and a 200-day moving average of $362.56. The firm has a market cap of $20.92 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same period in the previous year, the business earned $6.39 EPS. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. HC Wainwright lifted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Bank of America raised their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company lifted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.